Abstract Number: 843 • 2019 ACR/ARP Annual Meeting
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Background/Purpose: Risk factors for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a significant cause of morbidity and mortality, are poorly understood. RA-ILD detection is limited by…Abstract Number: 974 • 2019 ACR/ARP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Background/Purpose: Clinical development of BTK/Tec family kinase inhibitors for treating autoimmune diseases has lagged that of their successful application in oncology. The lack of selective…Abstract Number: 1177 • 2019 ACR/ARP Annual Meeting
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Background/Purpose: Near infrared (NIR) imaging of indocyanine green (ICG) in rheumatoid arthritis (RA) models identified abnormal lymphatic vessel (LV) function, which can be quantified as…Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…Abstract Number: 1372 • 2019 ACR/ARP Annual Meeting
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Background/Purpose: The adherence to the therapeutic regimen in patients with Rheumatoid Arthritis (RA) varies between 30 and 80%. Classically, it is mentioned that the adherence…Abstract Number: 1408 • 2019 ACR/ARP Annual Meeting
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Background/Purpose: Via a systematic literature review of contemporary efficacy data of pharmacological therapies in RA we sought to inform the 2019 update of the EULAR…Abstract Number: 1440 • 2019 ACR/ARP Annual Meeting
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Background/Purpose: Therapeutic drug monitoring (TDM) would be important if there was evidence to support the utility of measured drug concentrations in making changes to dose…Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…Abstract Number: 2005 • 2019 ACR/ARP Annual Meeting
Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune inflammatory disease causing erosive and disabling joint damage. We recently found that mitochondria are extruded upon formation of…Abstract Number: 2163 • 2019 ACR/ARP Annual Meeting
Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014
Background/Purpose: Total knee arthroplasty (TKA) is a valuable option for improving function and pain control in patients with end-stage arthritis, especially those with inflammatory arthritis…Abstract Number: 2302 • 2019 ACR/ARP Annual Meeting
Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis
Background/Purpose: Our objectives were (1) to identify similarities and differences of pain symptoms identified by fibromyalgia (FM) and neuropathic pain (NP) screening tool (2) to…Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…Abstract Number: 2368 • 2019 ACR/ARP Annual Meeting
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Background/Purpose: Several studies have reported an increased risk of gastro-intestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) compared to conventional synthetic…Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 56
- Next Page »